developmentstoday

Ask DT AI Audio Brief Videos Podcast +

Ask DT AI Audio Brief Videos Podcast

HomeTagsNature Medicine

#Nature Medicine

All articles tagged with "Nature Medicine"

Company

About Us
Advertise
Contact
Editorial Policy

Legal

Terms of Service
Privacy Policy
Cookie Policy
AI & Ethics Policy
Do Not Sell My Info
FAQ
Archive
Site Map

Discover

Newsletter
Ask DT AI
Audio Brief
Videos
Podcast
DT Premium

Connect

Twitter / X
Facebook
LinkedIn
YouTube
Instagram
TikTok
Flipboard
RSS Feed

© 2026 Developments Today. All rights reserved.

Nature Medicine Articles | Developments Today

$Nature Medicine on X: "In a phase 1 trial, #CD19 #CART treatment of patients with severe, treatment-refractory #RheumatoidArthritis was mostly safe with clinical improvement seen in all patients. https://t.co/QY60Z3cV4s" / X (via x.com)$

Phase 1 CAR-T trial points to a new path for severe rheumatoid arthritis

Nature Medicine published phase 1 results from the ongoing COMPARE trial on August 27, 2026.
Six patients with severe, treatment-refractory, ACPA-positive rheumatoid arthritis received a single infusion of miv-cel.
The study evaluates an autologous fully human CD19 CAR-T therapy aimed at B-cell depletion in autoimmune disease.

DE

DT Editorial Team·Aug 31, 2026·via nature.com

More in Health→

Species-Specific Evolution of Ebola Virus during Replication in Human and Bat Cells - ScienceDirect (via www.sciencedirect.com)

Experimental Ebola PEP Offers Early Human Signal

Nature Medicine published a case series on MBP134 used as post-exposure prophylaxis after Bundibugyo ebolavirus exposure.
Five people from a single family cluster received the investigational antibody cocktail 5 to 6 days after exposure.
The report says administration was well tolerated, with no treatment-related adverse events reported in the provided text.

DE

DT Editorial Team·Aug 25, 2026·via nature.com

More in Health→

The trials of translating psilocybin treatment from research to practice | Nature Medicine (via www.nature.com)

The trials of translating psilocybin treatment from research to practice

Nature Medicine published a psilocybin feasibility trial online on 21 August 2026.
The trial delivers psilocybin-assisted therapy for treatment-resistant depression within the UK health service.
The article highlights practical challenges in translating psychedelic research into routine clinical practice.
Workforce training, regulatory barriers, and facility requirements are central translation hurdles.

DE

DT Editorial Team·Aug 23, 2026·via nature.com

More in Health→

Putting epigenetic aging clocks on trial | Nature Medicine (via www.nature.com)

Study Tests 16 Epigenetic Aging Clocks Against Longevity Interventions

Nature Medicine published a study evaluating 16 different epigenetic aging clocks.
The study tested responsiveness to a broad array of pharmacological and lifestyle interventions.
This is one of the largest comparative analyses of epigenetic clocks in longevity research.
Findings could help researchers choose the right clock for clinical trials and consumer tests.

DE

DT Editorial Team·Aug 23, 2026·via nature.com

More in Health→

The px1 locus is linked to declining susceptibility to malaria drugs in Uganda | Nature Medicine (via www.nature.com)

Study Links px1 Locus to Declining Malaria Drug Susceptibility in Uganda

A study in Nature Medicine identifies the px1 locus as a potential genetic marker for declining drug susceptibility in Ugandan malaria parasites.
The finding could enable earlier detection of resistance and guide treatment policy changes.
Researchers emphasize the need for integrating genetic surveillance into routine malaria control programs.

DE

DT Editorial Team·Aug 20, 2026·via nature.com

More in Health→

Traumatic Brain Injury Market Size Analysis Report 2026-2030 (via www.thebusinessresearchcompany.com)

Global TBI study finds outcome gaps don’t track cleanly with development levels

A 29-country study tracked 2,165 traumatic brain injury patients across 100 hospitals.
Traffic injuries dominated low-HDI settings, while falls dominated very-high-HDI settings.
Adjusted mortality was highest in the high-HDI tier relative to the very-high-HDI tier.
Researchers argue that prevention and prehospital care may reduce TBI burden more effectively than hospital measures alone.

DE

DT Editorial Team·Aug 20, 2026·via nature.com

More in Health→

Correspondence | Nature Medicine (via www.nature.com)

Regulatory Fragmentation: The Hidden Barrier to Regional Vaccine Sovereignty

Regulatory fragmentation across countries and regions is a significant barrier to regional vaccine sovereignty.
Inconsistent standards and duplicative approval processes delay vaccine deployment and increase costs.
Local manufacturers, especially smaller ones, are disproportionately burdened by fragmented regulations.
Harmonization strategies include strengthening regional bodies, adopting international standards, and fostering regulatory reliance.

DE

DT Editorial Team·Aug 15, 2026·via nature.com

More in Health→

How to build an AI-driven digital organism | Nature Medicine (via www.nature.com)

Building AI-Driven Digital Organisms: A New Frontier in Biomedicine

AI-driven digital organisms are virtual replicas of living systems that learn and adapt.
They could transform drug discovery by simulating drug interactions before human trials.
Personalized digital twins could guide treatment decisions for individual patients.
Technical challenges include data integration, computational power, and privacy concerns.

DE

DT Editorial Team·Aug 15, 2026·via nature.com

More in Health→

Challenges and perspectives of heart repair with pluripotent stem cell-derived cardiomyocytes | Nature Cardiovascular Research (via www.nature.com)

Nature Medicine Issues Expression of Concern for Stem Cell Heart Study

Nature Medicine published an editorial expression of concern for a study on stem cells refreshing adult cardiomyocytes after injury.
The expression was posted online on August 12, 2026.
The original study used genetic fate-mapping and suggested stem cells contribute to new heart muscle cells after injury.
The journal has not specified the nature of the concerns.

DE

DT Editorial Team·Aug 15, 2026·via nature.com

More in Health→

Step by Step—How to Prevent Type 2 Diabetes | Diabetes | CDC (via www.cdc.gov)

Type 2 diabetes prevention should start before disease takes hold

A Nature Medicine perspective argues diabetes prevention should focus on prediabetes remission rather than waiting for established dysglycemia.
The authors describe type 2 diabetes risk as cumulative across the life course, with critical windows of metabolic vulnerability.
They call for precision prevention that matches mechanistic differences while remaining scalable and affordable across settings.

DE

DT Editorial Team·Aug 11, 2026·via nature.com

More in Health→

Large-scale whole-genome sequencing reveals the landscape and health implications of de novo mutations | Nature Medicine (via www.nature.com)

Genome study links parental age, ART, and new mutations

Researchers sequenced 24,030 individuals across 7,851 parent-offspring families.
Maternal and paternal aging showed distinct mutation patterns.
Some ART procedures were associated with specific increases in de novo mutations.

DE

DT Editorial Team·Aug 9, 2026·via nature.com

More in Health→

A new front in the fight against malaria: Experimental bed nets halt parasite growth inside mosquitoes (via developmentstoday.com)

THC Trial Cuts PTSD Nightmares in 10-Week Study

A randomized controlled trial found dronabinol reduced nightmare frequency and intensity in adults with PTSD.
The study assigned 171 patients to dronabinol or placebo for 10 weeks of bedtime treatment.
Serious adverse events occurred in seven patients on dronabinol and none on placebo.
The authors said long-term efficacy and safety still need further evaluation.

DE

DT Editorial Team·Aug 5, 2026·via nature.com

More in Health→

Phase 1 Trial Shows Intracranial CAR-T Therapy for Recurrent Glioblastoma Is Safe and Feasible (via Bing Images) (via developmentstoday.com)

Explainable AI helps and harms in skin diagnosis study

Researchers studied 623 lay people and 153 primary care physicians using AI support for dermatological diagnosis.
A fairness-constrained model improved accuracy and reduced skin-tone-related disparities across both groups.
LLM-based explanations increased automation bias among lay users, while physicians remained comparatively resilient.

DE

DT Editorial Team·Aug 5, 2026·via nature.com

More in Health→

Non-Invasive Tests for the Detection of MASLD: Biomarkers and Imaging for Staging Steatosis, MASH, and Fibrosis - PMC (via pmc.ncbi.nlm.nih.gov)

Non-invasive liver scans show potential to replace some biopsies in MASLD

A Nature Medicine research briefing summarizes results from the LITMUS imaging study in MASLD.
Elastography and elastography-based composite scores showed enough accuracy to evaluate advanced fibrosis and cirrhosis.
The study found that current markers were not accurate enough to diagnose MASH without biopsy.
The findings support a more targeted role for liver biopsy rather than full replacement across all MASLD assessments.

DE

DT Editorial Team·Aug 4, 2026·via nature.com

More in Health→

Integrated care pathway in individuals with Long COVID: STIMULATE-ICP, a cluster-randomized, phase 3 trial - Nature Medicine

Long COVID trial finds integrated care helps, but MRI adds little

A phase 3 trial followed 1,152 adults with Long COVID across six NHS clinics in England.
Fatigue improved across all groups over 12 weeks under integrated multidisciplinary care.
Adding multi-organ MRI did not significantly improve the primary fatigue outcome versus usual care.
Digital rehabilitation also showed only modest differences, though researchers say it may still help in longer-term management.

DE

DT Editorial Team·Aug 2, 2026·via nature.com

More in Health→

Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS - Nature Medicine

ALS blood-protein study points to earlier prediction window

Researchers analyzed 516 serial plasma samples across converters, ALS patients, carriers and controls.
A 19-protein panel predicted phenoconversion across six-month to five-year windows.
The model estimated time to phenoconversion with a mean absolute error of 1.6 years.
UK Biobank data partially replicated the findings and supported the multi-protein approach.

DE

DT Editorial Team·Jul 30, 2026·via nature.com

More in Health→

$FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial - Nature Medicine$

Phase 1 trial suggests cevostamab could widen options in heavily pretreated multiple myeloma

A phase 1 trial tested cevostamab in 324 patients with relapsed or refractory multiple myeloma.
Most participants had heavily pretreated disease, and nearly half had prior BCMA-targeted therapy.
The drug produced a 42.1% objective response rate and a median response duration of 11.2 months.
The maximum tolerated dose was not reached, though serious adverse events were common.

DE

DT Editorial Team·Jul 25, 2026·via nature.com

More in Health→

Biological aging clocks in health and disease - Nature Medicine

Biological Aging Clocks: New Metrics to Track Health and Disease

Biological clocks measure aging at molecular, cellular, tissue, and organ levels.
Different organs age at different rates within the same individual.
Accelerated organ aging is prognostic for disease and mortality.
Cell-type-specific clocks identify drivers of neurodegeneration.

DE

DT Editorial Team·Jul 10, 2026·via nature.com

More in Health→

Influenza Challenge Study Links Fast Innate Response to Symptoms and Viral-Fighting Immunity

A controlled influenza challenge infected 22 of 27 volunteers, with 18 developing symptoms and four remaining asymptomatic.
Symptomatic participants showed faster and stronger innate immune activation early in infection.
That early activation also tracked with stronger later natural killer and CD8+ T cell responses.
Baseline immune responsiveness differed before exposure, suggesting predisposition helps shape disease course.

DE

DT Editorial Team·Jul 2, 2026·via nature.com

More in Health→

HemaGuide AI matched specialist tumor board decisions in blood cancer cases

Nature Medicine published a study on June 30, 2026 describing HemaGuide, a locally deployable AI agent for hematological malignancies.
The system converts unstructured records into structured cases, routes them to specialized decision modes, and grounds outputs in guidelines and more than 2,000 prior tumor board cases.
In blinded benchmarking on 45 complex cases, the study says HemaGuide improved concordance with tumor board decisions and completed workflows with a median latency of 39 seconds.

DE

DT Editorial Team·Jul 1, 2026·via nature.com

More in Health→

1
2
Next